News
The investment will fund a new drug manufacturing facility in Virginia, and expand research and development in at least 5 ...
The pharmaceutical giant said second-quarter revenue increased to $14.46 billion from $12.94 billion. U.S. revenue was up 13% ...
Investors were clearly impressed by the company's second-quarter beats, especially the one on the bottom line.
AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...
British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence ...
InsideNoVa on MSN10d
AstraZeneca to build its largest-ever manufacturing facility in Virginia, creating hundreds of jobsIn a vote of confidence for Virginia’s growing life sciences sector, pharmaceutical giant AstraZeneca announced plans to ...
AstraZeneca beat second-quarter earnings expectations on Tuesday, helped by strong sales of key cancer, heart and kidney ...
AstraZeneca's CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing ...
British-Swedish pharmaceutical company AstraZeneca announced a $50 billion investment in the U.S. this week, with the Trump ...
Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...
AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...
Zacks Investment Research on MSN21h
Here's Why Astrazeneca (AZN) is a Strong Momentum StockTaking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback